It allows for an increase in levodopa dosage without significant adverse effects
It decreases the risk of adverse effects of abnormal movements and psychiatric symptoms
It inhibits the conversion of levodopa to dopamine in the intestines and in tissue outside the central nervous system
It decreases the adverse effects such as nausea and vomiting
It adds to the therapeutic effect because carbidopa more readily crosses the blood brain barrier than levodopa